Can a cyclo-oxygenase type-2 selective tocolytic agent avoid the fetal side effects of indomethacin?
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 11281476.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We evaluated the efficacy and safety of nimesulide (100 mg orally twice daily for > 48 hours) in a pilot series of five women (two with twin pregnancies) at 24(+6) weeks (range 21(+3) - 27(+2)) in preterm labour which was unresponsive to intravenous ritodrine. Nimesulide therapy was continued for eight days (5-16) and was associated with a prolongation of pregnancy of 27 days (6-69). Oligohydramnios occurred in all seven fetuses after three to nine days of therapy, and in the five pregnancies that continued after discontinuation of nimesulide, it resolved within four days (2-7). None of the babies manifested permanent renal damage.
Medical subject headings
- Cyclooxygenase Inhibitors
- Obstetric Labor, Premature
- Oligohydramnios
- Sulfonamides
- Tocolytic Agents